<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538355</url>
  </required_header>
  <id_info>
    <org_study_id>IGEL</org_study_id>
    <nct_id>NCT01538355</nct_id>
  </id_info>
  <brief_title>A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis</brief_title>
  <acronym>IGEL</acronym>
  <official_title>A Randomised Controlled Pilot Study to Compare the Effects of Prolonged Fasting and Ketogenic Low Glycemic Load Treatment on Health Related Quality of Life in Relapsing-remitting Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well accepted that nutrition as an environmental factor is involved in the pathogenesis
      of multiple sclerosis. But is there a role for prolonged fasting and ketogenic low glycemic
      load treatment to alter the course of multiple sclerosis (MS)? The investigators think yes
      there is. Primarily the investigators want to detect if these diets are feasible for MS
      patients. Therefore the investigators examine the impact of this dietary intervention on the
      health related quality of life for individuals after 7 days, 3 months and 6 months in compare
      to baseline. Secondarily the investigators focus on endocrinological and immunological
      changes after 7 days, 3 months and 6 months in compare to baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this controlled randomised pilot study the patients are allocated to 1. a ketogenic low
      glycemic load treatment from the outset of the study for 24 weeks or 2. enhance their regular
      diet with an initial 7-day fasting followed by a Mediterranean diet pattern until the study
      end or 3. stay on their regular diet (control group) from the outset of the study for 24
      weeks. The investigators will then assess the differences between the groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Multiple Sclerosis Quality of Life-54 questionnaire: Proof of feasibility at 6 months.</measure>
    <time_frame>Visit: Baseline, month 1, month 3 and month 6</time_frame>
    <description>Two summary scores: physical health und mental health, 12 subscales and 2 single item scales.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence rates, number of participants with adverse events and laboratory parameters at 6 months.</measure>
    <time_frame>Visits: Baseline, month 1, month 3 and month 6</time_frame>
    <description>Multiple sclerosis functional composite; fatigue scores, body composition; body weight; lipid profile, liver enzymes, insulin, glucagon</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Prolonged fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo an initial 7-day fasting episode.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketogenic low glycemic load treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a ketogenic low glycemic load treatment from the outset of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients stay on their regular diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prolonged Fasting</intervention_name>
    <description>Patients enhance their regular diet with an initial 7-day fasting episode.</description>
    <arm_group_label>Prolonged fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ketogenic low glycemic load treatment</intervention_name>
    <description>6 months of ketogenic low glycemic load treatment from the study outset.</description>
    <arm_group_label>Ketogenic low glycemic load treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control diet</intervention_name>
    <description>Patients stay on their regular diet.</description>
    <arm_group_label>Control diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing remitting MS

          -  Stable immunomodulatory treatment or no treatment at least 6 months prior to inclusion

          -  Expanded disability status scale &lt; 7

          -  Body mass index (BMI) &gt; or = 18,5 OR BMI &gt; or = 45 with no risk factors

          -  Not pregnant or breast-feeding

          -  No serious mental health illness such as dementia or schizophrenia;

          -  No use of a weight loss therapy in the month prior to screening.

        Exclusion Criteria:

          -  Start or changes if immunomodulatory treatment &lt; 7 months prior to screening

          -  SPMS or PPMS

          -  Relapse or corticosteroid use &lt; 30 days prior to screening

          -  Diabetes or any metabolic defects

          -  Bulimia

          -  Anorexia

          -  Drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Bock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité-Universitätsmedizin Berlin, Berlin Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité-Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Piccio L, Stark JL, Cross AH. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J Leukoc Biol. 2008 Oct;84(4):940-8. doi: 10.1189/jlb.0208133. Epub 2008 Aug 4.</citation>
    <PMID>18678605</PMID>
  </reference>
  <reference>
    <citation>Kim DY, Hao J, Liu R, Turner G, Shi FD, Rho JM. Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS One. 2012;7(5):e35476. doi: 10.1371/journal.pone.0035476. Epub 2012 May 2.</citation>
    <PMID>22567104</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>February 15, 2015</last_update_submitted>
  <last_update_submitted_qc>February 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Markus Bock, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>diet</keyword>
  <keyword>prolonged fasting</keyword>
  <keyword>caloric restriction</keyword>
  <keyword>ketogenic low glycemic load treatment</keyword>
  <keyword>health related quality of life</keyword>
  <keyword>ketogenic diet</keyword>
  <keyword>neurodegeneration</keyword>
  <keyword>neuroinflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

